<?xml version='1.0' encoding='utf-8'?>
<document id="28430398"><sentence text="Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions."><entity charOffset="58-69" id="DDI-PubMed.28430398.s1.e0" text="Palbociclib" /></sentence><sentence text="Palbociclib free base capsule is a weak base drug with highly pH-dependent solubility" /><sentence text=" In vitro and in vivo studies evaluated the impact of acid-reducing agents on exposure of palbociclib and determined whether the impact, if any, can be mitigated by food"><entity charOffset="90-101" id="DDI-PubMed.28430398.s3.e0" text="palbociclib" /></sentence><sentence text=" A drug-drug interaction study (study 1) was conducted first under fasted conditions and showed that coadministration of multiple doses of the proton-pump inhibitor rabeprazole substantially reduced palbociclib mean area under the concentration-time curve from time 0 to infinity and maximum observed plasma concentration by 62% and 80%, respectively"><entity charOffset="165-176" id="DDI-PubMed.28430398.s4.e0" text="rabeprazole" /><entity charOffset="199-210" id="DDI-PubMed.28430398.s4.e1" text="palbociclib" /><pair ddi="false" e1="DDI-PubMed.28430398.s4.e0" e2="DDI-PubMed.28430398.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28430398.s4.e0" e2="DDI-PubMed.28430398.s4.e1" /></sentence><sentence text=" In vitro assessment suggested that the presence of bile salt mixed micelles to mimic the fed state can significantly enhance the solubility of palbociclib"><entity charOffset="144-155" id="DDI-PubMed.28430398.s5.e0" text="palbociclib" /></sentence><sentence text=" Subsequently, study 2 was conducted under fed conditions and demonstrated that coadministration of rabeprazole decreased palbociclib maximum observed plasma concentration by 41% but had limited impact on area under the concentration-time curve from 0 to infinity (13% decrease)"><entity charOffset="100-111" id="DDI-PubMed.28430398.s6.e0" text="rabeprazole" /></sentence><sentence text=" This study also showed that the histamine-2 receptor antagonist famotidine and local antacid with staggered dosing had no impact on palbociclib exposure under fed conditions"><entity charOffset="65-75" id="DDI-PubMed.28430398.s7.e0" text="famotidine" /><entity charOffset="133-144" id="DDI-PubMed.28430398.s7.e1" text="palbociclib" /><pair ddi="false" e1="DDI-PubMed.28430398.s7.e0" e2="DDI-PubMed.28430398.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28430398.s7.e0" e2="DDI-PubMed.28430398.s7.e1" /></sentence><sentence text=" Food intake effectively mitigated the impact of acid-reducing agents on palbociclib exposure"><entity charOffset="73-84" id="DDI-PubMed.28430398.s8.e0" text="palbociclib" /></sentence><sentence text=" Palbociclib free base capsule should be taken with food, and acid-reducing agent use does not need to be avoided" /><sentence text="" /></document>